Table 2 Baseline characteristics of the study population according to the tertiles of the TyG index
Variables | Tertile 1 (n = 175) | Tertile 2 (n = 176) | Tertile 3 (n = 175) | p-value |
|---|---|---|---|---|
TyG index | 8.18 ± 0.26 | 8.72 ± 0.13 | 9.39 ± 0.36 |  < 0.001 |
General conditions | ||||
 Age (years) | 45.22 ± 6.27 | 43.35 ± 6.03 | 44.89 ± 6.48 | 0.012 |
 Male, n (%) | 98 (56.0) | 117 (66.5) | 101 (57.7) | 0.099 |
 BMI (kg/m2) | 26.25 ± 2.98 | 26.98 ± 3.49 | 27.47 ± 3.49 | 0.003 |
 LVEF (%) | 59.13 ± 10.84 | 59.81 ± 9.80 | 59.66 ± 9.32 | 0.799 |
 Admission for MI, n (%) | 36 (20.6) | 63 (35.8) | 54 (30.9) | 0.006 |
 GS | 31.00 (17.00–52.00) | 36.50 (22.00–59.50) | 45.00 (27.00–65.00) |  < 0.001 |
 Multivessel disease, n (%) | 73 (41.7) | 82 (46.6) | 78 (44.6) | 0.653 |
Risk factors, n (%) | ||||
 Current smoking | 43 (24.6) | 51 (29.0) | 54 (30.9) | 0.406 |
 Current drinking | 31 (17.7) | 39 (22.2) | 29 (16.6) | 0.367 |
 FH-CAD | 27 (15.4) | 48 (27.3) | 69 (39.4) |  < 0.001 |
 DM | 11 (6.3) | 24 (13.6) | 68 (38.9) |  < 0.001 |
 Hypertension | 94 (53.7) | 107 (60.8) | 98 (56.0) | 0.393 |
 Hyperlipidemia | 15 (8.6) | 63 (35.8) | 98 (56.0) |  < 0.001 |
Laboratory test | ||||
 FPG (mmol/L) | 4.54 (4.17–4.89) | 4.91 (4.57–5.73) | 5.81 (5.06–7.97) |  < 0.001 |
 TC (mmol/L) | 3.73 (3.12–4.26) | 4.02 (3.37–4.77) | 4.57 (3.70–5.35) |  < 0.001 |
 TG (mmol/L) | 1.01 (0.84–1.19) | 1.49 (1.32–1.80) | 2.21 (1.79–2.71) |  < 0.001 |
 LDL-C (mmol/L) | 2.27 (1.71–2.69) | 2.54 (2.00–3.13) | 2.85 (2.07–3.54) |  < 0.001 |
 HDL-C (mmol/L) | 1.20 ± 0.26 | 1.16 ± 0.23 | 1.17 ± 0.27 | 0.495 |
 eGFR (mL/min/1.73m2) | 118.55 ± 24.11 | 116.47 ± 27.53 | 119.18 ± 26.25 | 0.595 |
 UA (μmol/L) | 310.26 ± 80.11 | 324.40 ± 87.37 | 331.10 ± 95.52 | 0.078 |
Cardiovascular medications, n (%) | ||||
 Antiplatelet drugs | 164 (93.7) | 168 (95.5) | 165 (94.3) | 0.767 |
 Stains | 168 (96.0) | 164 (93.2) | 169 (96.6) | 0.279 |
 Beta-blockers | 103 (58.9) | 111 (63.1) | 108 (61.7) | 0.711 |
 ACEI/ARB | 62 (35.4) | 91 (51.7) | 93 (53.1) | 0.001 |
 Hypoglycemic drugs | 11 (6.3) | 19 (10.8) | 60 (34.3) |  < 0.001 |
Outcomes, n (%) | ||||
 MACE | 20 (11.4) | 36 (20.5) | 45 (25.7) | 0.003 |
 All-cause death | 2 (1.1) | 1 (0.6) | 3 (1.7) | 0.543 |
 Cardiovascular death | 1 (0.6) | 1 (0.6) | 3 (1.7) | 0.544 |
 Non-fatal MI | 5 (2.9) | 10 (5.7) | 14 (8.0) | 0.108 |
 Coronary artery revascularization | 12 (6.9) | 23 (13.1) | 27 (15.4) | 0.037 |
 Non-fatal stroke | 1 (0.6) | 2 (1.1) | 1 (0.6) | 1.000 |